Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
Revenue Growth %: -6.5%
Financial Fact:
Income from operations: 1.43B
Today's EPS Names:
CRMT, More
Revenue Growth %: -6.5%
Financial Fact:
Income from operations: 1.43B
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.67, $0.24 better than the analyst estimate of $3.43. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.31 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.49.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
